Precision immunomics medicines
Location: United Kingdom
Total raised: $51.16M
Investors 2
| Date | Name | Website |
| 09.02.2024 | Martlet | martletcap... |
| 04.07.2023 | Manta Ray ... | mantaray.v... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 21.01.2026 | Seed | $35.1M | Octopus Ve... |
| 02.05.2024 | Seed | $16.06M | - |
Mentions in press and media 15
| Date | Title | Description |
| 24.01.2026 | Infinitopes Secures $35.1M to Advance Precision Cancer Vaccine | Infinitopes, an Oxford-based biotechnology firm, has significantly expanded its seed financing. The company secured an additional $15.4 million. This latest infusion brings total seed funding to $35.1 million. The capital directly targets c... |
| 21.01.2026 | Infinitopes Expands Seed Round To $35.1 Million To Advance Precision Cancer Vaccine Into First-In-Human Trial | Infinitopes has expanded its seed financing to $35.1 million, adding $15.4 million in a second close that the company says will accelerate clinical development of its lead precision cancer vaccine candidate, ITOP1. The financing was co-led ... |
| 21.01.2026 | Infinitopes Raises $15.4M in Seed Extension Funding | Infinitopes, an Oxford, UK-based clinical-stage cancer vaccine biotechnology company, raised additional $15.4M in Seed funding. The round was co-led by Octopus Ventures and new investor Amplify Bio, with participation from new investor Macm... |
| 11.06.2025 | London Tech Week day 3: Let’s use that NHS budget on tech | From NHS waiting lists to global warming, if we get it right we can use technology to address our biggest challenges, writes Russ Shaw in day three of his Tech Week diary The UK tech ecosystem has always punched above its weight. But wherea... |
| 08.11.2024 | Infinitopes: Pioneering the Future of Cancer Vaccines | In the world of cancer treatment, hope often feels like a flickering candle in a storm. Yet, a new player is emerging, determined to turn that flicker into a blazing beacon. Infinitopes, a biotech company born from the halls of Oxford Unive... |
| 08.11.2024 | The Future of Vision and Immunotherapy: Innovations from AllFocal Optics and Infinitopes | In the world of technology and healthcare, two companies are pushing boundaries. AllFocal Optics and Infinitopes are not just making waves; they are creating tsunamis of innovation. Each is tackling a unique challenge: enhancing human visio... |
| 08.11.2024 | Infinitopes to Showcase Breakthroughs on Cancer Vaccine Development at SITC 2024: Insight into a double-blind, Phase I/IIa clinical trial | Infinitopes' lead vaccine candidate ITOP1 is a novel, precision targeted, immunologically durable, "off-the-shelf" cancer vaccine, designed to save lives by preventing disease recurrence in first-line patients with surgically rese... |
| 09.05.2024 | Infinitopes' Article in Peer-Reviewed Journal Seeks to Unlock the Potential of Cancer Vaccines | Publication in Human Vaccines and Immunotherapeutics highlights progress in understanding tumour biology and vaccine technologies since the pandemic OXFORD, England, May 9, 2024 /PRNewswire/ -- Infinitopes Precision Immunomics, an integrate... |
| 09.05.2024 | Infinitopes' Article in Peer-Reviewed Journal Seeks to Unlock the Potential of Cancer Vaccines | Publication in Human Vaccines and Immunotherapeutics highlights progress in understanding tumour biology and vaccine technologies since the pandemic OXFORD, England, May 9, 2024 /PRNewswire/ -- Infinitopes Precision Immunomics, an integrate... |
| 02.05.2024 | Integrated cancer biotech Infinitopes secures £12.8m seed financing to enhance its Precision Immunomics™ antigen discovery technologies to target five more cancers | Funding also supports the start of phase I/IIa study for lead vaccine, ITOP1 OXFORD, England, May 2, 2024 /PRNewswire/ -- Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen ... |
Show more